• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Biotech Startup Lantern Pharma Raises $3.7M to Accelerate Cancer Drug Approval Process

by HITC Staff 05/02/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Clinical-Stage Biotech Startup Lantern Pharma Raises $3.7M to Accelerate Cancer Drug Approval Process

Clinical-stage biotech company Lantern Pharma Inc. has raised $3.7 million in Series A funding led by BIOS Partners, GPG Ventures and other private investors. Using big data and artificial intelligence, Lantern Pharma focused exclusively on accelerating the cancer drug approval process.

The startup plans to utilize the funding to continue development of its two lead drug candidates and further the advancement of its big data and Artificial Intelligence (AI) platform. Lantern’s strategy focuses on identifying partners or acquiring late-stage clinical drugs that show efficacy in a small number of patients. These abandoned drugs are ‘rescued and repurposed’ using molecular profiling to identify the patients who respond favorably to treatment. Responding patients are screened for a biomarker, stratified and treated in a narrow scope of clinical trials. This process of targeting certain genomic profiles creates truly targeted therapies and addresses a significant unmet need in the cancer market.

The company’s lead clinical-stage drug candidate Tavocept® (LP-300) has previously shown clinical efficacy in a sub-set of non-small cell lung cancer patients in combination regimens. Its second program LP-184 has demonstrated promising early anti-tumor activity for multiple solid tumors, especially gynecologic tumors, and a favorable safety profile, and has the potential to be a best-in-class product. Lantern has identified predictive biomarkers for both Tavocept and LP-184 using its proprietary techniques combining advanced genomics, big data and AI-based algorithms.

“Oncology compounds have undergone tremendous advancements in design, but have lacked the systematic analysis leveraging big data and precision trial design and testing, which has led to inefficient processes and lackluster approval rates,” said Dr. Arun Asaithambi, co-founder and CEO of Lantern Pharma. “At Lantern we are developing targeted biomarker panels that can precisely sub-type patients based on the ability to be responsive to a treatment. Then by incorporating that into the selection and testing process, we can save years and tens of millions of dollars, thereby, making treatments more personalized and accessible. We believe this will lead to better outcomes, efficient and faster drug development.”

Lantern out-licensed its first program Irofulven-1 for a total of up to $20M to a European pharma company. Additionally, Lantern was issued an $800,000 collaborative ICIP grant funding. Recently, the company initiated collaborations with genomics diagnostic leaders, Cancer Genetics Inc, for genomic data access, laboratory testing and analysis services.

 

 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Big Data Cancer, Biotech, Biotech startups, Cancer Drug Approval, Lantern Pharma

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |